0001144204-16-076252.txt : 20160120 0001144204-16-076252.hdr.sgml : 20160120 20160120155141 ACCESSION NUMBER: 0001144204-16-076252 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160115 FILED AS OF DATE: 20160120 DATE AS OF CHANGE: 20160120 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ReWalk Robotics Ltd. CENTRAL INDEX KEY: 0001607962 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: KOCHAV YOKNEAM BUILDING, FLOOR 6 STREET 2: P.O. BOX 161 CITY: YOKNEAM ILIT STATE: L3 ZIP: 20692 BUSINESS PHONE: 97249590123 MAIL ADDRESS: STREET 1: KOCHAV YOKNEAM BUILDING, FLOOR 6 STREET 2: P.O. BOX 161 CITY: YOKNEAM ILIT STATE: L3 ZIP: 20692 FORMER COMPANY: FORMER CONFORMED NAME: Argo Medical Technologies Ltd. DATE OF NAME CHANGE: 20140513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dykan Jeff CENTRAL INDEX KEY: 0001661229 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36612 FILM NUMBER: 161350993 MAIL ADDRESS: STREET 1: KOCHAV YOKNEAM BUILDING, FLOOR 6 STREET 2: P.O. BOX 161 CITY: YOKNEAM ILIT STATE: L3 ZIP: 20692 4 1 v429214_form4.xml OWNERSHIP DOCUMENT X0306 4 2016-01-15 0 0001607962 ReWalk Robotics Ltd. RWLK 0001661229 Dykan Jeff C/O REWALK ROBOTICS, LTD. 3 HATNUFA ST. P.O. BOX 161 YOKNEAM ILIT L3 20692203 ISRAEL 1 0 1 0 Ordinary Shares, par value NIS 0.01 per share 2016-01-15 4 S 0 50000 10.2968 D 1772100 I By partnership Ordinary Shares, par value NIS 0.01 per share 6022 I ESOP Transaction made pursuant to a Rule 10b5-1 trading plan adopted on December 15, 2015. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.0000 to $10.8500, inclusive. The reporting person undertakes to provide to ReWalk Robotics Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The Reporting Person is a director of SCP Vitalife II GP, Ltd. ("SCP Vitalife GP"), which is the sole general partner of SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"). SCP Vitalife Associates is the sole general partner of each of SCP Vitalife Partners II, L.P. ("SCP Vitalife") and SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife Israel"), the direct beneficial owner of the Ordinary Shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of the Shares held by SCP Vitalife and SCP Vitalife Israel, except to the extent of his pecuniary interest therein. SCP Vitalife Associates, as the general partner of SCP Vitalife and SCP Vitalife Israel, may be deemed to beneficially own 1,619,574 Ordinary Shares, which consist of 1,214,076 and 405,498 Ordinary Shares held by SCP Vitalife and SCP Vitalife Israel, respectively. SCP Vitalife GP is the general partner of SCP Vitalife Associates and, as such, shares voting and dispositive power over, and may be deemed to beneficially own, the Ordinary Shares held by the foregoing entities. The Reporting Person shares voting and dispositive power over, and may be deemed to beneficially own 1,772,100 Ordinary Shares, which consist of the Ordinary Shares as set forth in footnote 5 to this Form 4. Consists of 1,619,574 Ordinary Shares held by the foregoing entities due to the Reporting Person serving as a director of SCP Vitalife GP, as well as (i) 68,011 Ordinary Shares held by Vitalife Partners (Overseas) L.P. ("Vitalife Partners Overseas"), (ii) 22,493 Ordinary Shares held by Vitalife Partners (Israel) L.P. ("Vitalife Partners Israel"), (iii) 22,741 Ordinary Shares held by Vitalife Partners (D.C.M) L.P. ("Vitalife Partners DCM", and together with Vitalife Partners Overseas and Vitalife Partners Israel, the "Vitalife I Entities") and (iv) 39,281 Ordinary Shares currently held by the Office of the Chief Scientist of the State of Israel ("OCS"), that the Vitalife I Entities have the right to acquire from the OCS, due to the Reporting Person serving as a director of Vitalife Life Sciences Ltd., the general partner of Vitalife Partners Management L.P., which is the general partner of each of the Vitalife I Entities. Represents 6,022 ordinary shares issuable upon the vesting of restricted stock units ("RSUs") granted on December 15, 2014 under the ReWalk 2014 Equity Incentive Plan. The RSUs vest in 12 equal quarterly installments starting on the first anniversary of the date of grant, with 2,007 ordinary shares presently issued and outstanding. /s/ Kevin Hershberger, as attorney-in-fact 2016-01-20